MARKET

APRE

APRE

Aprea Therapeutics, Inc.
NASDAQ
0.6094
+0.0167
+2.82%
After Hours: 0.5804 -0.029 -4.76% 19:58 02/13 EST
OPEN
0.5868
PREV CLOSE
0.5927
HIGH
0.6439
LOW
0.5610
VOLUME
184.64K
TURNOVER
--
52 WEEK HIGH
3.880
52 WEEK LOW
0.5480
MARKET CAP
4.26M
P/E (TTM)
-0.2847
1D
5D
1M
3M
1Y
5Y
1D
Aprea Therapeutics Secures New Patents in 2025, Expanding Global IP Portfolio for DDR Cancer Therapies
Reuters · 1d ago
Aprea announces expansions of its global intellectual property estate
TipRanks · 1d ago
Aprea Therapeutics Enhance Patent Portfolio In Australia, Japan For Its WEE1, ATR Programs
Benzinga · 1d ago
APREA THERAPEUTICS INC - EXISTING ISSUED PATENTS EXPECTED TO REMAIN IN FORCE THROUGH 2035-2037
Reuters · 1d ago
Aprea Therapeutics Secures New Patents in Australia and Japan to Strengthen Global DDR Cancer Therapy Portfolio
Reuters · 2d ago
APREA THERAPEUTICS STRENGTHENS GLOBAL PATENT PORTFOLIO IN DNA DAMAGE RESPONSE (DDR) CANCER THERAPEUTICS, PAVING WAY FOR PIPELINE GROWTH
Reuters · 2d ago
Aprea Therapeutics Price Target Cut to $7.00/Share From $11.00 by Wedbush
Dow Jones · 3d ago
Aprea Therapeutics Is Maintained at Outperform by Wedbush
Dow Jones · 3d ago
More
About APRE
Aprea Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on precision oncology through synthetic lethality. The Company’s pipeline includes two clinical-stage synthetic lethality programs. Its lead programs are APR-1051, an oral, small-molecule inhibitor of WEE1 kinase, and ATRN-119, a small-molecule ATR inhibitor, both in clinical development for solid tumor indications. Its ATRN-119 is an oral small molecule inhibitor of ataxia telangiectasia and Rad3-related (ATR). The ATR kinase is a master regulator of Deoxyribonucleic Acid (DNA) damage response, with roles in cell cycle control and DNA repair following replication stress. It is evaluating potential combination opportunities within its pipeline, including research on the combination of ATRN-119 and APR-1051 that is supported by a Phase II SBIR grant from the National Cancer Institute. It also has an early-stage program, in the lead optimization stage, for an undisclosed DNA-damage response (DDR) target.

Webull offers Aprea Therapeutics Inc stock information, including NASDAQ: APRE real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, APRE stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading APRE stock methods without spending real money on the virtual paper trading platform.